Printer Friendly

Belgian UCB to buy commercial rights on Novartis drugs.

(ADPnews) - Aug 24, 2009 - Belgian UCB SA (EBR:UCB) said Monday it had agreed to buy the commercial rights in Germany on cardiovascular and diabetes products of Swiss pharmaceutical maker Novartis AG (VTX:NOVN).

The biopharmaceutical company will expand its pipeline with the cardiovascular drug Provas and anti-hypertension product Dafiro.

In addition, UCB will co-commercialise the two new oral anti-diabetics Jalra and Icandra.

UCB is extending its cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options, which is in line with its ambition to offer the best medicines to its patients, said Willy Cnops, vice president UCB and managing director Germany.

COPYRIGHT 2009 AII Data Processing Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ADP News Belgium
Date:Aug 24, 2009
Words:105
Previous Article:Belgian Sonaca to axe up to 500 jobs - report.
Next Article:Belgian Leasinvest H1 2009 net current profit jumps 25% y/y.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters